

Helsinki, 21 August 2020

Addressees

Registrants of JS-MeTHF listed in the last Appendix of this decision

Date of submission for the jointly submitted dossier subject of a decision

28 October 2019

Registered substance subject to this decision, hereafter 'the Substance'

Substance name: Tetrahydro-2-methylfuran

EC number: 202-507-4

CAS number: 96-47-9

Decision number: [Please refer to the REACH-IT message which delivered this communication (in format TPE-D-XXXXXXXXXX-XX-XX/F)]**DECISION ON A TESTING PROPOSAL**

Based on Article 40 of Regulation (EC) No 1907/2006 (REACH), ECHA requests that you submit the information listed below by the deadline of **28 February 2022**.

Requested information must be generated using the Substance unless otherwise specified.

A. Requirements applicable to all the Registrants subject to Annex X of REACH

1. Extended one-generation reproductive toxicity study (Annex X, Section 8.7.3.; test method: OECD TG 443) in rats, oral route specified as follows:
 - Ten weeks pre-mating exposure duration for the parental (P0) generation;
 - Dose level setting shall aim to induce systemic toxicity at the highest dose level;
 - Cohort 1A (Reproductive toxicity);
 - Cohort 1B (Reproductive toxicity) without extension to mate the Cohort 1B animals to produce the F2 generation.

You must report the study performed according to the above specifications. Any expansions of the study design must be scientifically justified.

2. Pre-natal developmental toxicity study (Annex X, Section 8.7.2.; test method OECD TG 414) in a second species (rabbit), oral route.

Conditions to comply with the requests

You are bound by the requests for information corresponding to the REACH Annexes applicable to your own registered tonnage of the Substance at the time of evaluation. Therefore you have to comply with the requirements of Annexes VII to X of REACH, if you have registered a substance at above 1000 tpa.

Registrants are only required to share the costs of information they are required to submit to fulfil the information requirements for their registration.

The Appendices state the reasons for the requests for information to fulfil the requirements set out in the respective Annexes of REACH.

The Appendix entitled Observations and technical guidance addresses the generic approach for the selection and reporting of the test material used to perform the required studies and provides generic recommendations and references to ECHA guidance and other reference documents.

You must submit the information requested in this decision by the deadline indicated above in an updated registration dossier and also update the chemical safety report, where relevant, including any changes to classification and labelling, based on the newly generated information.

Appeal

This decision can be appealed to the Board of Appeal of ECHA within three months of its notification. An appeal, together with the grounds thereof, has to be submitted to ECHA in writing. An appeal has suspensive effect and is subject to a fee. Further details are described under: <http://echa.europa.eu/regulations/appeals>.

Approved¹ under the authority of Christel Schilliger-Musset, Director of Hazard Assessment

¹ As this is an electronic document, it is not physically signed. This communication has been approved according to ECHA's internal decision-approval process.

Appendix A: Reasons for the requirement applicable to all the Registrants subject to Annex X of REACH

This decision is based on the examination of the testing proposals you submitted.

1. Extended one-generation reproductive toxicity study (Annex X, Section 8.7.3.)

The basic test design of an extended one-generation reproductive toxicity study (EOGRTS) is a standard information requirement in Annex X to the REACH Regulation. Furthermore, column 2 of Section 8.7.3. defines when the study design needs to be expanded.

You have submitted a testing proposal for an EOGRTS according to OECD TG 443 by the oral route in rats with 10-week pre-mating exposure duration. You have provided the following specification of the study design according to the criteria described in Column 2 of Section 8.7.3, Annex X, and detailed in ECHA Guidance R.7a: *"The following specifications for the study are proposed:*

- *a basic study design*
- *10 weeks of pre-mating*
- *Species: Rat*
- *Route: Oral*
- *Dose levels to be selected based on existing toxicity data, taking into account the MTD and recommendations of the study guideline"*

You provided your considerations concluding that there were no alternative methods which could be used to adapt the information requirement(s) for which testing is proposed. ECHA has taken these considerations into account.

The following refers to the specifications of this required study.

Premating exposure duration and dose-level setting

You proposed 10 weeks for pre-mating exposure duration. ECHA agrees with your proposal.

Ten weeks pre-mating exposure duration is required because there is no substance specific information in the dossier supporting shorter pre-mating exposure duration as advised in the ECHA Guidance R.7a.

You proposed the dose levels to be selected based on existing toxicity data, taking into account the MTD and recommendations of the study guideline.

The highest dose level shall aim to induce systemic toxicity, but not death or severe suffering of the animals, to allow comparison of reproductive toxicity and systemic toxicity. The dose level selection should be based upon the fertility effects with the other cohorts being tested at the same dose levels.

If there is no existing relevant data to be used for dose level setting, it is recommended that results from a range-finding study (or range finding studies) are reported with the main study. This will support the justifications of the dose level selections and interpretation of the results.

You must provide a justification with your study report that demonstrate that the dose level selection meets the conditions described above.

Cohorts 1A and 1B

Cohorts 1A and 1B belong to the basic study design and shall be included.

Species and route selection

You proposed testing by oral route in rats. ECHA agrees with your proposal.

Outcome

Under Article 40(3)(a) of REACH, you are requested to carry out the proposed test with the Substance.

In your comments to the draft decision you inform ECHA that an EOGRTS (including the cohorts 1A, 1B, 2A, 2B and 3) is already ongoing and that "*the draft report is expected in July 2020*". You have also provided a study protocol and a statement, signed by the certified laboratory. You express your hopes that "*the information will be taken into account during the decision making process related to the Testing Proposal*".

Based on this information, ECHA shall take into account the newly generated data once the dossier update is provided.

A registration update with a robust study summary of the EOGRT study would need to be submitted to fulfil the information requirement of Annex X, Section 8.7.3. of the REACH Regulation. As you were already informed in the notification letter accompanying the initial draft decision of 26 March 2020, dossier updates will be considered in the follow-up evaluation which ECHA will perform after expiry of the deadline set by this decision.

ECHA notes that the design of the ongoing study includes the cohorts 1A, 1B, 2A, 2B and 3. Due to animal welfare reasons, you need to provide a justification for the expansion, as indicated below.

Further expansion of the study design

The conditions to include the extension of Cohort 1B are currently not met. Furthermore, no triggers for the inclusion of Cohorts 2A and 2B (developmental neurotoxicity) and Cohort 3 (developmental immunotoxicity) were identified. However, you may expand the study by including the extension of Cohort 1B, Cohorts 2A and 2B and/or Cohort 3 if relevant information becomes available from other studies or during conduct of this study. Inclusion is justified if the available information meets the criteria and conditions which are described in Column 2, Section 8.7.3., Annex IX/X. You may also expand the study due to other scientific reasons in order to avoid a conduct of a new study. The study design, including any added expansions, must be fully justified and documented. Further detailed guidance on study design and triggers is provided in ECHA Guidance².

2. Pre-natal developmental toxicity study (Annex X, Section 8.7.2.) in a second species

Pre-natal developmental toxicity (PNDT) studies on two species is the standard information requirement under Annex X, section 8.7.2, to REACH.

You have submitted a testing proposal for a PNDT study in a second species according to OECD TG 414.

² ECHA Guidance R.7a, Section R.7.6.

You provided your considerations concluding that there were no alternative methods which could be used to adapt the information requirement(s) for which testing is proposed. ECHA has taken these considerations into account.

You proposed a study with the rabbit as a second species. The study in the first species was carried out with rats. The rat or rabbit is the preferred species under the OECD TG 414³. On the basis of this default consideration, the study should be performed with the rabbit as a second species

You proposed administration by the oral route. ECHA agrees with your proposal. The oral route is the most appropriate route of administration to investigate reproductive toxicity³.

Under Article 40(3)(a) of REACH, you are requested to carry out the proposed study with the Substance.

³ ECHA Guidance R.7a Section R.7.6.2.3.2.

Appendix B: Procedural history

ECHA started the testing proposal evaluation in accordance with Article 40(1) on 29 October 2019.

ECHA held a third party consultation for the testing proposals from 27 January 2020 until 12 March 2020. ECHA did not receive information from third parties.

For the purpose of the decision-making, this decision does not take into account any updates of registration dossiers after the date on which you were notified the draft decision according to Article 50(1) of REACH.

The decision making followed the procedure of Articles 50 and 51 of REACH, as described below:

ECHA notified you of the draft decision and invited you to provide comments.

ECHA took into account your comments and amended the deadline.

Deadline to submit the requested information in this decision

In your comments to the draft decision you have indicated that the experimental phase of the EOGRTS had been initiated for other regulatory purposes and that the draft study report is expected to be available in July 2020. The deadline of 30 months initially set in the decision accommodated the time necessary to conduct the experimental phases of both the EOGRTS and the PNDT study and the subsequent reporting of this new information in a dossier update. Since the experimental phase for the EOGRTS is completed, and in order to obtain the new hazard information without undue delay, a deadline of 18 months allows for the PNDT study to be conducted and for all the new information to be submitted to ECHA. ECHA has amended the deadline to provide the information requested in this decision.

ECHA notified the draft decision to the competent authorities of the Member States for proposals for amendment.

As no amendments were proposed, ECHA adopted the decision under Article 51(3) of REACH.

Appendix C: Observations and technical guidance

1. This testing proposal examination decision does not prevent ECHA from initiating compliance checks at a later stage on the registrations present.
2. Failure to comply with the requests in this decision, or to otherwise fulfil the information requirements with a valid and documented adaptation, will result in a notification to the enforcement authorities of your Member State(s).

3. Test guidelines, GLP requirements and reporting

Under Article 13(3) of REACH, all new data generated as a result of this decision needs to be conducted according to the test methods laid down in a European Commission Regulation or according to international test methods recognised by the Commission or ECHA as being appropriate.

Under Article 13(4) of REACH, ecotoxicological and toxicological tests and analyses must be carried out according to the GLP principles (Directive 2004/10/EC) or other international standards recognised by the Commission or ECHA.

Under Article 10 (a) (vi) and (vii) of REACH, all new data generated as a result of this decision must be reported as study summaries, or as robust study summaries, if required under Annex I of REACH. See ECHA Practical Guide: 'How to report robust study summaries'⁴.

4. Test material

Selection of the test material(s)

The registrants of the Substance are responsible for agreeing on the composition of the test material to be selected for carrying out the tests required by the present decision. The test material selected must be relevant for all the registrants of the Substance, i.e. it takes into account the variation in compositions reported by all members of the joint submission. The composition of the test material(s) must fall within the boundary composition(s) of the Substance.

While selecting the test material you must take into account the impact of each constituent/impurity is known to have or could have on the test results for the endpoint to be assessed. For example, if a constituent/impurity of the Substance is known to have an impact on (eco)toxicity, the selected test material must contain that constituent/impurity.

Technical reporting of the test material

The composition of the selected test material must be reported in the respective endpoint study record, under the Test material section. The composition must include all constituents of the test material and their concentration values. Without such detailed reporting, ECHA may not be able to confirm that the test material is relevant for the Substance and to all the registrants of the Substance.

⁴ <https://echa.europa.eu/practical-guides>

Technical instructions are available in the manual "How to prepare registration and PPORD dossiers"⁵.

5. List of references of the ECHA Guidance and other guidance/ reference documents⁶

QSARs, read-across and grouping

Guidance on information requirements and chemical safety assessment, Chapter R.6 (version 1.0, May 2008), referred to as ECHA Guidance R.6 in this decision.

ECHA Read-across assessment framework (RAAF, March 2017)⁷

Toxicology

Guidance on information requirements and chemical safety assessment, Chapter R.7a (version 6.0, July 2017), referred to as ECHA Guidance R.7a in this decision.

Guidance on information requirements and chemical safety assessment, Chapter R.7c (version 3.0, June 2017), referred to as ECHA Guidance R.7c in this decision.

Environmental toxicology and fate

Guidance on information requirements and chemical safety assessment, Chapter R.7a (version 6.0, July 2017), referred to as ECHA Guidance R.7a in this decision.

Guidance on information requirements and chemical safety assessment, Chapter R.7b (version 4.0, June 2017), referred to as ECHA Guidance R.7b in this decision.

Guidance on information requirements and chemical safety assessment, Chapter R.7c (version 3.0, June 2017), referred to as ECHA Guidance R.7c in this decision.

PBT assessment

Guidance on information requirements and chemical safety assessment, Chapter R.11 (version 3.0, June 2017), referred to as ECHA Guidance R.11 in this decision.

Guidance on information requirements and chemical safety assessment, Chapter R.16 (version 3.0, February 2016), referred to as ECHA Guidance R.16 in this decision.

OECD Guidance documents

Guidance Document on aqueous-phase aquatic toxicity testing of difficult test chemicals – No 23, referred to as OECD GD 23.

Guidance Document on Standardised Test Guidelines for Evaluating Chemicals for Endocrine Disruption – No 150, referred to as OECD GD 150.

⁵ <https://echa.europa.eu/manuals>

⁶ <https://echa.europa.eu/guidance-documents/guidance-on-information-requirements-and-chemical-safety-assessment>

⁷ <https://echa.europa.eu/support/registration/how-to-avoid-unnecessary-testing-on-animals/grouping-of-substances-and-read-across>

Appendix D: List of the registrants to which the decision is addressed and the corresponding information requirements applicable to them

Registrant Name	Registration number	(Highest) Data requirements to be fulfilled
[REDACTED]	[REDACTED]	[REDACTED]

Note: where applicable, the name of a third party representative (TPR) may be displayed in the list of recipients whereas the decision is sent to the actual registrant.